Treating RA Archives | Page 3 of 14 | Rheumatoid Arthritis Warrior

Triple Therapy / Combination Therapy for Rheumatoid Arthritis

Treatments for Rheumatoid Arthritis In the past few decades, Rheumatoid Arthritis has been treated with therapies designed for other diseases. It was not always clear how these drugs treated Rheumatoid Arthritis / Rheumatoid Disease, but they were found to reduce immune activity in various ways. Because researchers recognized certain drugs could slow or modify progression of...Continue reading      5 Comments » Read more

Rheumatoid Arthritis (RA) Treat to Target

The treat to target (T2T) approach involves defining a treatment goal or “target” and modifying the therapy if the target is not reached. Treating to a target of remission or low disease activity Treat to target (T2T) is an approach to treating Rheumatoid Arthritis / Rheumatoid Disease (RD) that combines aggressive or intensive treatment with disease modifying...Continue reading      2 Comments » Read more

Efficacy of Xeljanz, Biologics, & DMARDs in Rheumatoid Disease

Why should I feel like I failed? I’m not alone We probably agree it’s unfair to say, “patients fail treatments” instead of the reverse, but there is still disappointment. I was optimistic that my Rheumatoid disease would respond to Xeljanz, the new oral DMARD (disease modifying anti-rheumatic drug) from Pfizer. Unfortunately, my joint stiffness and inflammation,...Continue reading      47 Comments » Read more

Ciprofloxacin / Fluoroquinolone Tendon Dangers with Rheumatoid Arthritis

My brief story about ciprofloxacin and Rheumatoid Arthritis I got a kidney infection shortly after starting Enbrel. It was Good Friday 2009. My kidney hurt and fever spiked to 104.5, after 3 days of UTI. Before then, I’d only had a minor UTI  with pregnancy. This is when my GP got the nickname “Good GP” because...Continue reading      37 Comments » Read more

Xeljanz Rejected by European Medicines Agency

EMA rejects Xeljanz authorization Late yesterday, the European Medicines Agency (EMA) rejected the Pfizer’s application to market Xeljanz (tofacitinib). The EMA application was refused because the Committee for Medicinal Products for Human Use (CHMP) “adopted a negative opinion” on approving Xeljanz, stating they were unconvinced its risks outweighed benefits. Last November, the FDA approved the 5mg...Continue reading      29 Comments » Read more
“imaware™
    Advertisement

Would You Like Free Email Updates?

Stay in touch with RA Warrior.

We respect your privacy. Your email address will never be shared.